



Research Article

Calycosin Ameliorates Inflammatory Paw Edema in Mice via Inhibiting NF- κ B Activation

¹Likun Cui, ²Yumei Han and ³Yukui Ma

¹College of Basic Medicine, Jining Medical University, 272067 Jining, Shandong, China

²Weifang People's Hospital, Shandong, China

³Shandong Provincial Key Laboratory of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, Shandong, China

Abstract

Background and Objective: Calycosin is recognized to exhibit a variety of pharmacological properties. This study investigated the anti-inflammatory effects and mechanisms of calycosin. **Materials and Methods:** Mice were randomly separated into six groups: Control, carrageenan (Car), calycosin (12.5, 25 and 50 mg kg⁻¹) and indomethacin (10 mg kg⁻¹). All groups were treated orally once per day for a week. One hour after the final treatment, paw edema was induced by using carrageenan in all groups except for the control group. The volumes of the paws were recorded 1, 3 and 5 h after carrageenan treatment and paw histopathological changes were assessed. Myeloperoxidase (MPO) activity and IL-1 β and TNF- α levels were analyzed by using ELISA. The expression of p-I κ B α in the cytoplasm and NF- κ B p65 in the nucleus were quantified using Western blotting. **Results:** Calycosin (25 and 50 mg kg⁻¹) significantly decreased paw edema and had protective effects on paw histopathological changes caused by carrageenan in mice. Further investigation demonstrated that calycosin (25 and 50 mg kg⁻¹) also decreased MPO activity, IL-1 β and TNF- α levels, expression of p-I κ B α in the cytoplasm and NF- κ B p65 in the nucleus. **Conclusion:** Collectively, these data indicated that calycosin displayed anti-inflammatory bioactivity through down-regulation of NF- κ B activation.

Key words: Calycosin, carrageenan, paw edema, anti-inflammation, bioactivity, NF- κ B activation, myeloperoxidase activity

Received: March 07, 2019

Accepted: April 30, 2019

Published:

Citation: Likun Cui, Yumei Han and Yukui Ma, 2019. Calycosin ameliorates inflammatory paw edema in mice via inhibiting NF- κ B activation. Int. J. Pharmacol., CC: CC-CC.

Corresponding Author: Yukui Ma, Shandong Provincial Key Laboratory of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences, 250101 Jinan, Shandong, China Tel: 008613065021182

Copyright: © 2019 Likun Cui *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

Inflammation is considered to be a pathophysiological feedback mechanism from the body towards numerous stimuli, including burns, microbial infections, allergens and mechanical injuries¹. Although such a reaction is defensive, inflammatory mediators and cytokines involved in the inflammatory cascade can often lead to pathological reactions including organ dysfunction and death². Macrophages play an important role during the development of an inflammatory response. Activated macrophages produce inflammatory mediators and cytokines that may cause damage^{3,4}. Therefore, compounds that control these factors can have anti-inflammatory properties. Non-steroidal anti-inflammatory drugs (NSAIDs) are considered to be the most common treatment for inflammatory diseases. The primary pharmacological effect of NSAIDs is prevention of prostaglandin synthesis by inhibition of the enzymatic function of COX. However, the applications of NSAIDs as anti-inflammatory drugs are limited by their adverse effects, such as gastric injury and ulceration, nephrotoxicity and bronchospasm⁵. Therefore, investigation of safer and less toxic drugs as alternatives to NSAIDs is urgently required.

Flavonoids are small molecules that exist in vegetables, fruit and medicinal plants. Previous studies have demonstrated that flavonoid compounds are bioactive in a variety of ways, including exhibiting anti-inflammatory⁶, antibacterial⁷, antioxidant⁸ and anticancer^{9,10} properties. Depending on their structure, flavonoid compounds can be categorized as flavonoids, isoflavones, chalcones, anthocyanins and flavanones, etc. Calycosin is a type of isoflavone and represents the active ingredient extracted from the traditional herb *Radix astragali*. Like many other flavonoid compounds, it has displayed strong anti-inflammatory activity in previous studies¹¹. It was shown to inhibit the production of pro-inflammatory cytokines in LPS-induced bone marrow-derived dendritic cells and rheumatoid arthritis synovial fibroblasts *in vitro*^{12,13}. Additionally, calycosin exhibited an anti-inflammatory effect by suppressing the expression of NO in LPS-induced RAW 264.7 cells¹⁴. Calycosin was shown to attenuate cerulein-induced acute pancreatitis *in vivo* through the MAPK and NF- κ B signaling pathways in mice¹⁵. Calycosin can also ameliorate DSS-induced acute colitis via regulation of the NF- κ B and JNK signaling pathways¹⁶. In addition, recent reports have found that calycosin can attenuate diabetes-induced renal inflammation through inhibition of NF- κ B activation both *in vitro* and *in vivo*¹⁷. However, the ability for calycosin to attenuate carrageenan-induced paw edema remains unexplored. This study was aimed to investigate the anti-inflammatory properties of calycosin,

the anti-inflammatory effects and mechanism of calycosin using an animal model of carrageenan-induced paw edema.

MATERIALS AND METHODS

Chemicals and materials: This research was conducted from March 6, 2018–October 10, 2018 at the Key Laboratory of Chemical Drugs, Shandong Academy of Pharmaceutical Sciences (Jinan, Shandong, China). Calycosin (purity>98%) was kindly provided by Xian Qinghe Biological Science and Technology Co., Ltd. (Xian, China). Indomethacin was purchased from Xian Bohua Pharmaceutical Co., Ltd. (Xian, China). Carrageenan was provided by Shanghai Hongshun Technology Co., Ltd. (Shanghai, China). The MPO, IL-1 β and TNF- α kits were purchased from Kejing Bio-Tech (Nanjing, China). The NF- κ B p65 and p-I κ B α antibodies were bought from Abcam (Cambridge, MA, USA).

Animals: Sixty male C57BL/6J mice (20–22 g) were obtained from Beijing Huafukang Animal Facility (Beijing, China). All mice were housed in standard conditions of ambient temperature (20 \pm 2°C) and humidity (50%–70%) by using a 12 h light/dark cycle. Mice had free access to food and water were acclimated to the conditions for 7 days prior to experimentation. This study was carried out in compliance with the regulations approved by the Animal Ethics Committee of Shandong Academy of Pharmaceutical Sciences (Serial number: IACUC-2018-009).

Experimental procedure: Animals were randomly allocated into 6 groups: Control, carrageenan, indomethacin (10 mg kg⁻¹) and calycosin (12.5, 25 and 50 mg kg⁻¹) groups of 10 mice each. All groups were treated orally once per day for a week in accordance with their grouping, with mice in the control and carrageenan groups treated with 1% carboxymethylcellulose sodium (10 ml kg⁻¹). One hour after the final treatment, paw edema was induced by subplantar injection of 30 μ L 1% carrageenan in normal saline into the right-hand paw, except for the control group. Paw volumes were measured by using a digital micrometer prior to and 1, 3 and 5 h after carrageenan injection. The percentage increase in paw volume was calculated by using the equation¹⁸:

$$\text{Increase (\%)} = \frac{V_c - V_t}{V_t} \times 100\%$$

where, V_c and V_t were pre and post-injection mouse paw volumes, respectively.

Measurement of biochemical parameters: The MPO activity, IL-1 β and TNF- α levels in paw tissue samples were measured

by ELISA according to methods described previously¹⁹. Animals were sacrificed 5 h after injection of carrageenan then paw samples were obtained from the carrageenan-injected and control groups. The tissue was then prepared for quantification of IL-1 β and TNF- α levels and MPO activity by ELISA.

Histopathological analysis: Paw tissue samples were collected and fixed in 10% formalin for 3 days, then decalcified in 10% nitric acid for 24 h. Tissue samples were dehydrated, fixed in paraffin and cut into 5 μ m sections. Hematoxylin and eosin (H and E) staining was performed to evaluate pathological changes.

Western blot analysis: Protein was extracted from the cytoplasm and nuclei of cells from 100 mg of paw tissue using an ExKine Protein Extraction Kit (AmyJet Scientific, Wuhan, China). Protein concentration was quantified by using a BCA kit (Cwbio, Beijing, China). Nucleoprotein and cytoplasmic proteins were separated using SDS-PAGE then transferred onto nitrocellulose membranes. Membranes were blocked using 5% skim milk and incubated with primary antibodies against p65 and p-I κ B α overnight at 4°C. After three washes with TBS-T, membranes were incubated with secondary antibodies for 1 h at room temperature. Finally, membranes were impregnated with ECL detection reagents after washing with TBS-T. Bands were visualized by using an LAS-4000 Image Reader (Fuji Film, Tokyo, Japan). Band intensities were quantified using Image Analysis Software (Rockville, MD, USA).

Statistical analysis: The SPSS (version 19.0) was used to process data, which are represented as Mean \pm SD.

Significance of differences were calculated using one-way ANOVA. The $p < 0.05$ was deemed significant.

RESULTS

Effect of calycosin paw edema: Pre-treatment with calycosin (25, 50 mg kg⁻¹) reduced the percentage increase in paw volume considerably following the injection of carrageenan ($p < 0.01$), indicating that calycosin suppressed carrageenan-induced paw edema. Indomethacin (10 mg kg⁻¹) also clearly inhibited paw edema after injection of carrageenan. The effect of calycosin (50 mg kg⁻¹) was a little weaker than indomethacin (Fig. 1).

Effect of calycosin histopathological changes: The effect of calycosin on paw histopathological changes was investigated as shown in Fig. 2a-f. The results demonstrated




Fig. 1: Effect of calycosin on carrageenan-induced paw edema
** $p < 0.01$ vs. the carrageenan group, Car: Carrageenan, Ind: Indomethacin




Fig. 2(a-f): Effect of calycosin on paw histological changes (H and E stain, magnification 200 \times), (a) Control group, (b) Carrageenan group, (c) Indomethacin group, (d-f) Calycosin (12.5, 25 and 50 mg kg⁻¹) groups
Arrows indicate site of inflammatory cell infiltration




Fig. 3: Effect of calycosin on MPO activity

##p<0.01 vs. the control group, **p<0.01 vs. the carrageenan group, Car: Carrageenan, Ind: Indomethacin

that the paw tissue from the control group presented a healthy tissue structure. Conversely, significant paw histopathological changes including the infiltration of neutrophils and lymphocytes were observed in the Car group (Fig. 2b). Inflammatory cells could be clearly observed in the calycosin (12.5 mg kg⁻¹) group (Fig. 2d). However, both indomethacin and calycosin (25, 50 mg kg⁻¹) significantly reduced inflammatory cell infiltration indicating that they induced a protective effect on carrageenan-induced paw histopathological changes (Fig. 2c, e, f).

Effect of calycosin on MPO activity: The MPO activity was significantly upregulated by carrageenan induction. Compared with the Car group, calycosin (25 and 50 mg kg⁻¹) reduced MPO activity (p<0.01). Indomethacin (10 mg kg⁻¹) also clearly suppressed MPO activity (p<0.01). Calycosin at 50 mg kg⁻¹ exhibited effects that were comparable to those of indomethacin (Fig. 3).

Effect of calycosin on IL-1β and TNF-α levels: Both IL-1β and TNF-α levels were significantly greater in the Car group. Compared with the Car group, calycosin (25, 50 mg kg⁻¹) caused a notable decrease in the levels of IL-1β and TNF-α. Indomethacin (10 mg kg⁻¹) also induced a considerable decrease in IL-1β and TNF-α levels. Calycosin at 50 mg kg⁻¹ exhibited effects comparable to those caused by indomethacin (Fig. 4).

Effect of calycosin on NF-κB p65 and p-IκBα expression: The expression of NF-κB p65 nucleoprotein was markedly





Fig. 4(a-b): Effect of calycosin on IL-1β and TNF-α levels, (a) IL-1β and (b) TNF-α levels were measured by ELISA

##p<0.01 vs. control group, **p<0.01 vs. carrageenan group, Car: Carrageenan, Ind: Indomethacin

increased in the Car group. In comparison, calycosin (25, 50 mg kg⁻¹) and indomethacin significantly reduced this expression (p<0.01). The expression of cytoplasmic p-IκBα was also significantly greater in the Car group. Calycosin (25, 50 mg kg⁻¹) and indomethacin demonstrated considerable inhibition of the expression of p-IκBα in the cytoplasm in comparison to the Car group (Fig. 5).

DISCUSSION

This study investigated the anti-inflammatory effects and the possible mechanisms of action of calycosin using a carrageenan-induced mouse paw edema model. The results




Fig. 5(a-c): Effect of calycosin on NF-κB p65 and p-IκBα expression, (a) Western blot analysis, (b) Expression of NF-κB p65 normalized against Histone H3 and (c) expression of p-IκBα normalized against β-actin

^{##}p<0.01 vs. the control group, ^{**}p<0.01 vs. the carrageenan group, Car: Carrageenan, Ind: Indomethacin

demonstrated that calycosin significantly reduced paw edema and inhibited paw histopathological changes induced by carrageenan. In addition, calycosin significantly decreased MPO activity, IL-1β and TNF-α levels, the expression of p-IκBα in the cytoplasm and NF-κB p65 in the nucleus in the paw tissues of mice.

The carrageenan-induced inflammatory paw edema animal model is one which is highly reproducible that has been widely used to evaluate anti-inflammatory agents¹⁸. The model is believed to be effective in the study of inflammation-related mediators and cytokines produced during an inflammatory response^{20,21}. The inflammatory model is considered to be a biphasic event. The final phase, post-1 h is principally caused by the infiltration of neutrophils that secrete pro-inflammatory mediators and cytokines after the 0-1 h early phase²². This study demonstrated that calycosin effectively reduced paw edema induced by carrageenan suggested that calycosin exhibits an anti-inflammatory action. In this regard, consistent with the results described above, previous findings have demonstrated that calycosin can exert a fine anti-inflammatory effect by inhibiting NO production in macrophages¹⁴. In addition,

previous studies have reported that calycosin was also found to attenuate cerulein-induced acute pancreatitis and DSS-induced acute colitis^{15,16}.

The anti-inflammatory effect of calycosin might be related to the reduction in neutrophil infiltration and production of pro-inflammatory cytokines. Leukocytes, especially neutrophils (PMN), act in a pivotal role in the inflammatory response. Myeloperoxidase (MPO) is an enzyme that catalyzes the reduction of peroxides, the most reliable index for evaluating aggregation and infiltration of PMN in tissue. Therefore, the degree of MPO activity in local tissues can reflect the degree of PMN aggregation and infiltration, qualitatively²³. The results demonstrated that 25 and 50 mg kg⁻¹ of calycosin significantly decreased MPO activity, which suggested that calycosin could reduce neutrophil infiltration at the site of an inflammatory response. The results above mirrored previous studies^{15,16}. Pro-inflammatory cytokines are increased during an inflammatory response and play key roles in the development of various inflammatory diseases²⁴. The TNF-α can activate macrophages and T cells leading to an immune response. The TNF-α is also able to stimulate the release of other inflammatory cytokines.

Similarly, IL-1 β is regarded as the most important inflammatory cytokine produced by macrophages. The release of IL-1 β can cause cell death or tissue damage during an inflammatory response²⁵. To investigate the effects of calycosin on inflammatory cytokines, its anti-inflammatory effects were evaluated using a paw edema model. The results demonstrated that 25 and 50 mg kg⁻¹ calycosin clearly decreased the levels of IL-1 β and TNF- α in a dose dependent manner. In this regard, previous studies have demonstrated that calycosin was able to suppress the expression of pro-inflammatory cytokines in LPS-induced bone marrow-derived dendritic cells and rheumatoid arthritis synovial fibroblasts^{12,13}.

Many studies have revealed that the control of inflammation is closely related to the nuclear transcription factor kappa B (NF- κ B) signalling pathways^{26,27}. The NF- κ B consists of five components: RelA (p65), RelB, p50, p52 and cRel. The main form of NF- κ B comprises homodimers and heterodimers of p50 and p65 subunits. Previous studies have shown that activated NF- κ B triggers transcriptional upregulation of pro-inflammatory cytokines including IL-6, IL-1 β and TNF- α . Therefore, the regulation of NF- κ B signaling pathway activation should reduce the severity of inflammatory damage. In a resting state, the inhibitory subunit of the I κ B protein can tightly bind to NF- κ B dimers, which further capture NF- κ B in the cytoplasm. I κ B α can be phosphorylated by the I κ B kinase (IKK) complex. Phosphorylated I κ B proteins are degraded by proteasomes that trigger the ingress of NF- κ B to the nucleus. Once NF- κ B enters, the transcription of various inflammatory cytokines is induced to generate an inflammatory response in local tissues²⁸⁻³⁰. In this study, the expression of p-I κ B α and NF- κ B p65 in the cytoplasm/nucleus were closely monitored and studied. Results demonstrated that calycosin at 25 and 50 mg kg⁻¹ significantly inhibited the expression of p-I κ B α in the cytoplasm and NF- κ B in the nucleus in comparison with the Car group. This suggested that the phosphorylation of I κ B α in the cytoplasm is decreased and the nuclear translocation process of NF- κ B is suppressed, preventing NF- κ B entering the nucleus to induce the production of pro-inflammatory factors. A number of previous studies supported the observation that calycosin can inhibit the activation of NF- κ B^{17,31,32}. Although, the present research demonstrated that calycosin exhibits strong anti-inflammatory activity, demonstrating prodigious potential as a therapeutic drug, the anti-inflammatory effects and mechanism of action of calycosin should be further studied in other inflammatory models.

CONCLUSION

The findings of this study demonstrated that calycosin possessed anti-inflammatory activity with a mechanism that was possibly mediated by the inhibition of NF- κ B activation. These results support the pharmacological basis of calycosin for the treatment of various inflammatory illnesses.

SIGNIFICANCE STATEMENT

This study has discovered the anti-inflammatory effect of calycosin in a carrageenan-induced paw edema animal model that can be beneficial for the treatment of various inflammatory illnesses. This finding may help researchers find more effective anti-inflammatory drugs by structural modification of calycosin.

ACKNOWLEDGMENTS

The work was supported by Supporting Fund for Teachers' research of Jining Medical University (JY2017KJ020).

REFERENCES

1. Ma, Y., Y. Li, X. Li and Y. Wu, 2013. Anti-inflammatory effects of 4-methylcyclopentadecanone on edema models in mice. *Int. J. Mol. Sci.*, 14: 23980-23992.
2. Schottenfeld, D. and J. Beebe-Dimmer, 2006. Chronic inflammation: A common and important factor in the pathogenesis of neoplasia. *CA Cancer J. Clin.*, 56: 69-83.
3. Zhang, X., H. Xiong and L. Liu, 2012. Effects of taraxasterol on inflammatory responses in lipopolysaccharide-induced raw 264.7 macrophages. *J. Ethnopharmacol.*, 141: 206-211.
4. Oh, Y.C., Y.H. Jeong, J.H. Ha, W.K. Cho and J.Y. Ma, 2014. Oryeongsan inhibits LPS-induced production of inflammatory mediators via blockade of the NF- κ B, MAPK pathways and leads to HO-1 induction in macrophage cells. *BMC Complement. Altern. Med.*, Vol. 14. 10.1186/1472-6882-14-242.
5. Shabbir, A., S.A. Batoool, M.I. Basheer, M. Shahzad and K. Sultana *et al.*, 2018. Ziziphora clinopodioides ameliorated rheumatoid arthritis and inflammatory paw edema in different models of acute and chronic inflammation. *Biomed. Pharmacother.*, 97: 1710-1721.
6. Rauf, A., G. Uddin, B.S. Siddiqui, H. Khan and S.U. Shah *et al.*, 2016. Antinociceptive and anti-inflammatory activities of flavonoids isolated from Pistacia integerrima galls. *Complement. Ther. Med.*, 25: 132-138.

7. Nobakht, M., S.J. Trueman, H.M. Wallace, P.R. Brooks, K.J. Streeter and M. Katouli, 2017. Antibacterial properties of flavonoids from kino of the eucalypt tree, *Corymbia torelliana*. *Plants*, Vol. 6. 10.3390/plants6030039.
8. Zhao, Y.J., J.K. Li, X. Zhang and J.P. Gao, 2018. [Study on antioxidant activity of flavonoids from leaves of *Psidium guajava*]. *Zhongguo Zhong Yao Za Zhi*, 43: 760-765.
9. Wang, Z.F., J. Liu, Y.A. Yang and H.L. Zhu, 2018. A review: The anti-inflammatory, anticancer, antibacterial properties of four kinds of licorice flavonoids isolated from licorice. *Curr. Med. Chem.* 10.2174/092986732566 6181001104550.
10. Patel, K., G.K. Singh and D.K. Patel, 2018. A review on pharmacological and analytical aspects of naringenin. *Chin. J. Integr. Med.*, 24: 551-560.
11. Gao, J., Z.J. Liu, T. Chen and D. Zhao, 2014. Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of radix astragali. *Pharm. Biol.*, 52: 1217-1222.
12. Li, W., Y.N. Sun, X.T. Yan, S.Y. Yang and S. Kim *et al.*, 2014. Flavonoids from astragalus membranaceus and their inhibitory effects on LPS-stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cells. *Arch. Pharm. Res.*, 37: 186-192.
13. Su, X., Q. Huang, J. Chen, M. Wang and H. Pan *et al.*, 2016. Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62/Nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts. *Pharmacol. Res.*, 113: 695-704.
14. Hu, T., Q.M. Liu, X.W. He, F. Huang, M.W. Zhang and J.G. Jiang, 2017. Identification of bioactives from *Astragalus chinensis* L.f. and their antioxidant, anti-inflammatory and anti-proliferative effects. *J. Food Sci. Technol.*, 54: 4315-4323.
15. Ma, R., F. Yuan, S. Wang, Y. Liu, T. Fan and F. Wang, 2018. Calycosin alleviates cerulein-induced acute pancreatitis by inhibiting the inflammatory response and oxidative stress via the p38 MAPK and NF- κ B signal pathways in mice. *Biomed. Pharmacother.*, 105: 599-605.
16. Chao, L., P. Zheng, L. Xia, Y. Yong, G. Lu, F. Tang and Z. Zhao, 2017. Calycosin attenuates dextran sulfate sodium (DSS)-induced experimental colitis. *Iran. J. Basic Med. Sci.*, 20: 1056-1062.
17. Zhang, Y.Y., R.Z. Tan, X.Q. Zhang, Y. Yu and C. Yu, 2019. Calycosin ameliorates diabetes-induced renal inflammation via the NF- κ B pathway *in vitro* and *in vivo*. *Med. Sci. Monit.*, 25: 1671-1678.
18. Yonathan, M., K. Asres, A. Assefa and F. Bucar, 2006. *In vivo* anti-inflammatory and anti-nociceptive activities of *Cheilanthes farinosa*. *J. Ethnopharmacol.*, 108: 462-470.
19. Yang, J., S. Li, C. Xie, H. Ye, H. Tang, L. Chen and A. Peng, 2013. Anti-inflammatory activity of ethyl acetate fraction of the seeds of *Brucea javanica*. *J. Ethnopharmacol.*, 147: 442-446.
20. Li, Y.C., Y.F. Xian, S.P. Ip, Z.R. Su and J.Y. Su *et al.*, 2011. Anti-inflammatory activity of patchouli alcohol isolated from *pogostemonis herba* in animal models. *Fitoterapia*, 82: 1295-1301.
21. Liao, J.C., J.C. Tsai, W.H. Peng, Y.J. Chiu, P.J. Sung, M. Tsuzuki and Y.H. Kuo, 2013. Anti-inflammatory activity of *N*-(3-florophenyl)ethylcaffeamide in mice. *Int. J. Mol. Sci.*, 14: 15199-15211.
22. Santos, J.A., A. Arruda, M.A. Silva, C.A.L. Cardoso, M. do Carmo Vieira, C.A.L. Kassuya and A.C. Arena, 2012. Anti-inflammatory effects and acute toxicity of hydroethanolic extract of *Jacaranda decurrens* roots in adult male rats. *J. Ethnopharmacol.*, 144: 802-805.
23. Kassuya, C.A., A. Cremonese, L.F. Barros, A.S. Simas and R.L. Fda *et al.*, 2009. Antipyretic and anti-inflammatory properties of the ethanolic extract, dichloromethane fraction and costunolide from *Magnolia ovata* (Magnoliaceae). *J. Ethnopharmacol.*, 124: 369-376.
24. Dewanjee, S., T.K. Dua and R. Sahu, 2013. Potential anti-inflammatory effect of *Leea macrophylla* Roxb. leaves: A wild edible plant. *Food Chem. Toxicol.*, 59: 514-520.
25. Liang, Y., T. Shen, Q. Ming, G. Han, Y. Zhang, J. Liang and D. Zhu, 2018. Alpinetin ameliorates inflammatory response in LPS-induced endometritis in mice. *Int. Immunopharmacol.*, 62: 309-312.
26. Guolan, D., W. Lingli, H. Wenyi, Z. Wei, C. Baowei and B. Sen, 2018. Anti-inflammatory effects of neferine on LPS-induced human endothelium via MAPK and NF- κ B pathways. *Pharmazie*, 73: 541-544.
27. Jin, Y., F. Wei, X. Dai, M. Qi and Y. Ma, 2018. Anti-inflammatory effect of 4-methylcyclopentadecanone in rats submitted to ischemic stroke. *Fundam. Clin. Pharmacol.*, 32: 270-278.
28. Hayden, M.S. and S. Ghosh, 2008. Shared principles in NF- κ B signaling. *Cell*, 132: 344-362.

29. Oeckinghaus, A., M.S. Hayden and S. Ghosh, 2011. Crosstalk in NF- κ B signaling pathways. *Nat. Immunol.*, 12: 695-708.
30. Li, S., X. Liu, J. Lei, J. Yang, P. Tian and Y. Gao, 2017. Crocin protects podocytes against oxidative stress and inflammation induced by high glucose through inhibition of NF- κ B. *Cell Physiol. Biochem.*, 42: 1481-1492.
31. Quan, G.H., H. Wang, J. Cao, Y. Zhang and D. Wu *et al.*, 2015. Calycosin suppresses RANKL-mediated osteoclastogenesis through inhibition of MAPKs and NF- κ B. *Int. J. Mol. Sci.*, 16: 29496-29507.
32. Yang, J., M. Jia, X. Zhang and P. Wang, 2019. Calycosin attenuates MPTP induced Parkinson's disease by suppressing the activation of TLR/NF κ B and MAPK pathways. *Phytother. Res.*, 33: 309-318.